* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Infections in Organ Transplantation and Neutropenia1
Globalization and disease wikipedia , lookup
Transmission (medicine) wikipedia , lookup
Common cold wikipedia , lookup
Rheumatic fever wikipedia , lookup
Traveler's diarrhea wikipedia , lookup
Germ theory of disease wikipedia , lookup
Childhood immunizations in the United States wikipedia , lookup
Sociality and disease transmission wikipedia , lookup
Gastroenteritis wikipedia , lookup
Multiple sclerosis research wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Marburg virus disease wikipedia , lookup
Sarcocystis wikipedia , lookup
Hepatitis C wikipedia , lookup
Carbapenem-resistant enterobacteriaceae wikipedia , lookup
Hygiene hypothesis wikipedia , lookup
Hepatitis B wikipedia , lookup
Urinary tract infection wikipedia , lookup
Schistosomiasis wikipedia , lookup
Coccidioidomycosis wikipedia , lookup
Neonatal infection wikipedia , lookup
Infections in Organ Transplantation and Neutropenia Dr. Brian O’Connell Content 1. Introduction 2. Infections among asplenic patients 3. Infections among solid organ transplant recipients 4. Infections among patients with neutropenia Introduction ► Infection: result of an imbalance between host defences and virulence of the infecting organism ► Immunocompromised: deficits in the body’s natural defence mechanisms that predispose to infection ► Infection remains a significant cause of morbidity and mortality in this group of patients Host defences and associated pathogens Type of deficit Deficit Examples Organisms Local Breach of physical defences IV catheter, urinary catheter, surgical wound, tracheal intubation Bacteria, Candida. Generalised Deficits of: a) cell-mediated immunity a) a) Humoral immunity Phagocytic defenses a)Organ transplant, AIDS a) Intracellular, viruses, parasites, Listeria, Salmonella b) Chronic lymphocytic leukaemia, Myeloma, asplenia c) ALL, AML, Cytotoxic chemotherapy b) Capsulate bacteria c) Coliforms, Pseudomonas, Aspergillus. Classification of Pathogens ► Primary pathogens: May cause disease in normal host e.g. group A streptococci, M. tuberculosis. ► Sometime pathogens: Organisms that sometimes cause disease in normal hosts ► Opportunist pathogens: Organisms that virtually never cause disease in normal hosts ► Latent pathogens: Organisms that infect the normal host and are controlled but may recrudesce when immunocompromised eg. Toxoplasma gondii, Herpes simplex, Pneumocystsis carinii. Examples of opportunistic pathogens ► Coagulase-negative staphylococci Skin organism Commonest cause of bacteraemia in neutropenic patients in this hospital ► Pseudomonas aeruginosa Colonises gut and may cause bacteraemia with a high mortality And a necrotising skin condition ► Aspergillus species thousands of spores inhaled everyday Mortality of at least 65% when causes invasive disease ► Mycobacterium avium-intracellulare Environmental organism Systemic infection in HIV 1. Infections among asplenic patients ► Major lymphoid organ harbouring a significant amount of total immunoglobulin producing B-lymphocytes ► Mononuclear cells in splenic sinusoid phagocytose circulating bacteria, especially unopsonised organisms ► Spleen - main production site for opsonising antibodies ► Predisposed to infections caused by capsulate bacteria e.g. Streptococcus pneumoniae, Haemophilus influenzae type b, Neisseria meningitidis Also malaria and babesiosis (intra-erythrocytic parasites) ► Overwhelming post-splenectomy infection (OPSI) or post-splenectomy sepsis Significant increase (up to 600 fold) in risk of serious infection Dramatic presentation ► Lifetime risk Increased risk with younger patient Underlying disease Time since splenectomy ► Presentation: Short prodrome, fever, chills, sometimes diarrhoea Rapid progression ► Mortality: 50-70% despite maximal supportive care and appropriate antimicrobial therapy Interval from splenectomy to postsplenectomy sepsis (data from: Holdsworth Br J Surg 1991; 78: 1031-38) Cumulative % of PSS 120 100 80 60 40 20 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Years following splenectomy Prevention/Management ► Immunisation S. pneumoniae (23 valent) H. influenzae type b N. meningitidis group C Annual influenza vaccine meningococcus group A if travelling to an endemic area (i.e. Africa, India, Nepal, Pakistan, Saudi Arabia) ► Penicillin prophylaxis Lifelong Penicillin 333-666 mg BD or Erythromycin 250 mg BD, if penicillin allergic ► Patient awareness Patients developing signs of infection should be advised to seek medical attention urgently Patients should be provided with amoxycillin and advised to take 1 gm if symptoms develop and medical attention is likely to be delayed advised of the risks of travelling to areas where malaria is endemic - severe malaria may occur despite antimalarial prophylaxis ► Medic-alert bracelet 2. Infections among solid organ transplant recipients ► Early infections (<60 days) tend to be related to surgical procedure ► Late infections tend to be related to net state of immunosuppression and environmental exposure Type of transplant ► In general, kidney and heart transplant have less infective complications than liver and lung or heart/lung transplantation Factors that contribute to infection after transplantation ► Ill recipient Colonised with virulent and possibly resistant organisms Already receiving immunosuppressive drugs Prior latent infection e.g. Pneumocystis, CMV, TB ► Damaged organ ► ► ► Donor transmitted infections ► ► ► Surgical operation, ITU stay Immunosuppression Immunosuppressive element of some infections e.g. CMV, hepatitis C virus Donor transmitted infection ► Viral HIV, Hepatitis B, C ► Bacterial More common in lung transplantation than other solid organ transplants ► Protozoal Toxoplasmosis Bacterial and parasitic infections in solid organ transplant recipients Organ transplanted First 2 weeks Early Late Kidney Wound infection UTI UTI Liver Intraabdominal, Bacteraemia, Pneumonia Pulmonary aspergillosis, Cholangitis. Listeria monocytogenes, Toxoplasmosis, Pneumocystis, Cryptococcus neoformans, Nocardia spp. Heart/lung Mediastinitis, Empyema, pneumonia Pulmonary aspergillosis, Rubin NEJM 1998; 324: 1741 Onset of episodes of infection post liver transplantation 25 Blood 20 Bile 15 Peritoneal Pleural 10 No. of episodes of infection 5 Time post transplantation (days) >1 00 >9 0 80 + 70 + 60 + 50 + 40 + 30 + 6< 10 11 <1 5 16 <2 0 21 <2 5 25 <3 0 05 0 Approach to fever in organ transplant recipient ► Despite immunosuppressive therapy most patients with infection develop fever Note pneumocystis may present with dry cough and dyspnoea Cryptococcal meningitis may present with headache only ► History, physical exam and take relevant specimens, perform CXR ► Antibiotics may be withheld if patient appears well Prevention ► Pre-transplant screening for latent infection CMV, Toxoplasmosis ► Remove foci of infection ► Antibiotic prophylaxis For surgery sometimes for donor transmitted infection e.g. lung transplantation Long-term e.g CMV, pneumocystis, toxoplasmosis 4. Infections among patients with neutropenia Introduction ► Patients with neutropenia are at significant increased risk of infection ► Related to depth of neutropenia ► Mainly bacterial infections and less commonly fungal infection ► Do not present with signs of inflammation ► Infected neutropenic patients nearly always have fever ► Require prompt (within 1 hour) antimicrobial therapy Causes of fever among neutropenic patients Clinically documented infections 17% Unexplained fever 39% Microbiologically documented infections 44% Risk factors for bacteraemic infection in cancer patients depth of neutropenia <1.0 x 109/l <0.5 x 109/l <0.1 x 109/l ► duration of neutropenia ► mucosal damage e.g. HSV, chemotherapy induced mucositis ► right atrial catheters ► cellular immune defects ► defects of phagocyte function ► factors relating to the virulence of colonising organisms ► Infectious episodes (%) Episodes of severe infection related to number of circulating neutrophils 50 45 40 35 30 25 20 15 10 5 0 <0.1 01-0.5 0.5-1 Neutrophil count (10 9/L) Bodey Ann Inter Med 1966. 64:328-44 >1 Sources of bacteraemic infection Hickman catheter Bacterial translocation M-cells in Peyer’s patches phagocytose bacteria Mesenteric Lymph Node (MLN) Thoracic Duct Systemic Circulation Oropharyngeal mucositis Spectrum of organisms causing blood-steam infection ► Bacterial infections Gram positive ► Coagulase negative staphylococci ► Viridans streptococci ► Enterococci Gram-negative ► Enterobacteriaceae E. coli ► Non-fermentative GNB P. aeruginosa ► Fungal Infections Candida species % Single organism bacteraemias in EORTC trials of febrile neutropenia Gram (-) Gram (+) 20 18 16 14 12 10 8 6 4 2 0 I II III IV V VIII IX X XIV (1973- (1978- (1980- (1983- (1986- (1988- (1991- (1993- (199778) 80) 83) 86) 88) 90) 92) 94) 00) EORTC Trials Possible reasons for change in spectrum of organisms from Gram-negative to Gram-positive ► More severe oral mucositis ► More frequent use of indwelling catheters ► Selective pressure of antimicrobials – in particular cephalosporins and quinolones Quinolone prophylaxis Empiric antimicrobial therapy absence of clinical signs of inflammation ► Historical high mortality due to Gram-negative bacteraemia 90% in 1962 20% in 1978 <10% 2000 ► concept of empiric antimicrobial therapy ► Temperature > 38.50 C x 2 or >390 C x 1 Clinical examination, take blood cultures and commence broad-spectrum antibiotic therapy Which antibiotics? Principles: ► Controversial ► Bactericidal ► broad-spectrum with activity against Pseudomonas aeruginosa ► non-toxic ► choice depends upon institutional spectrum of infections, susceptibility pattern of infecting micro-organisms, individual clinical situation, cost and toxicity Established therapeutic regimens 1) Anti-pseudomonal B-lactam + aminoglycoside 2) Double B-lactam combination 3) Monotherapy with either ceftazidime, cefipime, meropenem or piperacillin-tazobactam 4) Any of the above regimens + vancomycin/teicoplanin ► Despite extensive clinical studies since the 1970s, no single empirical therapeutic regimen for the initial treatment of febrile patients with neutropenia can be recommended ► choice depends upon institutional spectrum of infections, susceptibility pattern of infecting micro-organisms and individual clinical situation Oral antimicrobial therapy for febrile neutropenia ► may be considered for patients: who have no focus of bacterial infection or Patients who do not have symptoms and signs suggesting systemic infection (e.g., rigors, hypotension) other than fever IDSA Guidelines: CID 2002; 34: 730-751 Prophylaxis against bacterial infections ► Oral quinolones are used in many centres for prophylaxis of bacterial infection ► Reuter et al. CID 2005;15: 1087-93 2 periods: ► 1 year with levofloxacin prophylaxis ► Without prophylaxis ► Stopped prematurely because of increased Gram-negative bacteraemia and increased mortality ► Cullen et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. NEJM 2005; 353: 988-998. Randomised, double blind trial 500mg levofloxacin od (784) v. placebo 781 Primary outcome – no. of febrile episodes In levofloxacin group: ► less febrile episodes (P<0.001) ► less hospitalisations (P=0.004) Fungal Infections Risk groups and incidence • autopsy data shows that up to 25% of neutropenic patients with leukaemia have evidence of fungal infection • allogeneic BMT ►85 autopsies - 26% had fungal infection • Risk depends upon: (Milliken 1990 RID, 12,S374) ►depth and duration of neutropenia ►GVHD ►age ►positive CMV serology Empiric treatment of fever of unknown origin administration of amphotericin B has become standard practice (Piizzo Am J Med 1982; 72: 101; EORTC Am J Med 1989; 86: 668) controversy about when to start dose is uncertain will not prevent emergence of IFI Fungal Pathogens 1. Candida species • • • • • C. albicans C. parapsilosis C. glabrata C. tropicalis C. krusei changing epidemiology ►increasing use of azoles ►increasing use of central intravascular catheters Clinical Syndromes Mucocutaneous disease • Localised disease • • Invasive disease ►acute disseminated candidiasis ►line-related candidaemia ►chronic disseminated candidiasis/hepatosplanic candidiasis Chronic disseminated candidiasis/hepatosplenic candidiasis 2. Aspergillus species A. fumigatus, A. flavus Clinical Syndromes • • • invasive pulmonary aspergillosis (IPA) ►focal or diffuse sinus disease cutaneous disease Epidemiology and Risk Factors associated with building works early (neutropenia >21 days) late (associated with GVHD) Diagnosis histological culture CT PCR antigen detection Halo sign 3. Mucormycosis Rhizopus, Absidia, Rhizomucor, Cunninghamella associated with prolonged neutropenia Clinical Syndromes rhinocerebral, pulmonary, cutaneous, disseminated characterised by fever and necrosis Diagnosis biopsy - histology and microbiology Rhinocerebral mucormycosis Histological appearance of mucormycosis Mucor species Lactophenol cotton blue stain of Rhizopus species 4. Other pathogenic fungi Fusarium spp. Alternaria spp. Pseudallescheria boydii Trichosporon spp. Malassezia furfur Disseminiated Fusarium infection